Germany approves trials of COVID-19 vaccine candidate [Reuters (UK)]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Reuters
Germany approves first trial of COVID-19 vaccine candidate - Reuters 1 Min Read BERLIN (Reuters) - Germany’s vaccines regulator approved live human testing of a potential vaccine against the Covid-19 virus developed by German biotech company BioNTech, the regulator said in a statement on Wednesday. The trial, only the fourth worldwide of a preventive agent targeting the virus behind the global pandemic, will be conducted on 200 healthy people aged between 18 and 55 in the first stage, and on further people, including those at higher risk from the disease, in a second stage. BioNTech said it was developing the vaccine candidate, named BNT162, together with its partner, pharma giant Pfizer. Tests of the vaccine were also planned in the United States, once regulatory approval for testing on humans had been secured there. Reporting by Thomas Escritt; Editing by Ludwig Burger All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2020 Reu
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $151.00 price target on the stock.MarketBeat
- BioNTech Achieves Minimum Condition in CureVac Exchange OfferGlobeNewswire
- BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time ExpirationGlobeNewswire
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.MarketBeat
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.MarketBeat
BNTX
Earnings
- 11/3/25 - Miss
BNTX
Sec Filings
- 12/3/25 - Form 6-K
- 11/28/25 - Form 144
- 11/26/25 - Form 6-K
- BNTX's page on the SEC website